Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1997 1
1998 1
1999 1
2001 1
2003 3
2006 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.
Kerbel RS. Kerbel RS. Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S134-9. Cancer Biol Ther. 2003. PMID: 14508091 Review.
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy.
Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F. Mancuso P, et al. Blood. 2006 Jul 15;108(2):452-9. doi: 10.1182/blood-2005-11-4570. Epub 2006 Mar 16. Blood. 2006. PMID: 16543470 Free PMC article. Clinical Trial.
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Bocci G, et al. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12917-22. doi: 10.1073/pnas.2135406100. Epub 2003 Oct 15. Proc Natl Acad Sci U S A. 2003. PMID: 14561896 Free PMC article.
Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results.
Kerbel RS. Kerbel RS. J Clin Oncol. 2001 Sep 15;19(18 Suppl):45S-51S. J Clin Oncol. 2001. PMID: 11560971 Review. No abstract available.
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. Bertolini F, et al. Cancer Res. 2003 Aug 1;63(15):4342-6. Cancer Res. 2003. PMID: 12907602 Free article.
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma.
Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O. Maelandsmo GM, et al. Int J Cancer. 1997 Aug 22;74(4):464-9. doi: 10.1002/(sici)1097-0215(19970822)74:4<464::aid-ijc19>;2-9. Int J Cancer. 1997. PMID: 9291441 Free article.
Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma.
Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS. Flørenes VA, et al. Oncogene. 1999 Jan 28;18(4):1023-32. doi: 10.1038/sj.onc.1202382. Oncogene. 1999. PMID: 10023678 Free article.
Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.
Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Okada F, et al. Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3609-14. doi: 10.1073/pnas.95.7.3609. Proc Natl Acad Sci U S A. 1998. PMID: 9520413 Free PMC article.
Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression.
Rak J, Mitsuhashi Y, Erdos V, Huang SN, Filmus J, Kerbel RS. Rak J, et al. J Cell Biol. 1995 Dec;131(6 Pt 1):1587-98. doi: 10.1083/jcb.131.6.1587. J Cell Biol. 1995. PMID: 8522614 Free PMC article.
Constitutive production of 92-kDa gelatinase B can be suppressed by alterations in cell shape.
MacDougall JR, Kerbel RS. MacDougall JR, et al. Exp Cell Res. 1995 Jun;218(2):508-15. doi: 10.1006/excr.1995.1185. Exp Cell Res. 1995. PMID: 7796886